Neurocrine Biosciences (NBIX) Tops Q4 EPS by 33c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $155.64 --0%
Revenue Growth %: +30.8%
Financial Fact:
Income (loss) from operations: -38.44M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +30.8%
Financial Fact:
Income (loss) from operations: -38.44M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $1.54, $0.33 better than the analyst estimate of $1.21. Revenue for the quarter came in at $515.2 million versus the consensus estimate of $518.2 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
- AsiaStrategy adds Bitcoin-backed credit facility with Asian institution
- UBS Downgrades Lai Yih Footwear Co Ltd (6890:TT) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
